Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

MACK $9.21 1.3400 +17.03%
TGTX $11.93 1.7100 +16.73%
ATRA $34.18 4.2100 +14.05%
RXDX $9.35 1.1500 +14.02%
GLYC $5.65 0.6699 +13.45%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

SNSS $0.90 -0.0485 -5.11%
GALT $2.25 -0.0900 -3.85%
CLBS $1.48 -0.0300 -1.99%
RDHL $12.55 -0.2300 -1.80%
VBLT $7.71 -0.1200 -1.53%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | Next > | Last >>

Genetic Clue To Breast Cancer Relapses

(BBC News) Sept 25, 2015 - A research team from the Wellcome Trust Sanger Institute in Cambridge found that cancers that return were more likely to contain certain genes or combinations of genes.
read article 

Roche Skin Cancer Combination Therapy Gets EU Panel Backing

(Reuters) Sept 25, 2015 - Roche is expecting the European Commission this year to issue a final decision on a drug combination to treat advanced skin cancer, based on a drug panel's positive opinion made public on Friday.
read article 

ICD-10: One Week Out

(The CMS Blog) Sept 24, 2015 - In one week, the U.S. health care system will start using the International Classification of Diseases, 10th Revision.
read article 

Novartis Rolls Out Access Program For Cheap Medicines To Treat Chronic Diseases In Select Countries

(International Business Times) Sept 24, 2015 - Novartis AG said on Thursday it will provide 15 drugs that treat chronic diseases for just $1 per treatment per month to government, nonprofit organizations and public healthcare providers in low-income countries.
read article 

F.D.A. Panel Discusses Essure Contraceptive Implant

(New York Times) Sept 24, 2015 - A panel of experts convened by the Food and Drug Administration was weighing the evidence Thursday on a contraceptive device that has received thousands of complaints from women who say they were harmed by it.
read article 

Startup's Cancer Test for the Healthy May Harm Public, FDA Says

(Bloomberg) Sept 24, 2015 - The Food and Drug Administration said Thursday that a health-care startup’s cancer detection kit sold to healthy individuals is high-risk, could harm public health, and hasn’t been validated by science.
read article 

Cornell Dots Research Collaboration Leads to $10M Cancer Center

(Cornell Chronicle/Cornell University) Sept 24, 2015 - Cornell University, in partnership with Memorial Sloan Kettering Cancer Center (MSKCC), is opening a new $10 million Center of Cancer Nanotechnology Excellence that brings together scientists, engineers, biologists and physicians to develop and translate new cancer care applications based on nanotechnology.
read article 

Robert D. Schreiber, PhD, and Philip D. Greenberg, MD, Named New Editors-in-chief of AACR Journal Cancer Immunology Research

(AACR) Sept 24, 2015 - The American Association for Cancer Research (AACR) recently announced the appointment of Robert D. Schreiber, PhD, and Philip D. Greenberg, MD, as editors-in-chief of Cancer Immunology Research, one of eight peer-reviewed journals published by the AACR.
read press release 

New York State Approves Columbia University’s 467-Gene Cancer Panel

(CUMC) Sept 23, 2015 - The Laboratory of Personalized Genomic Medicine at Columbia University Medical Center (CUMC) has been granted full approval by the New York State Department of Health for the Columbia Combined Cancer Panel, (CCCP).
read press release 

Pipeline Drugs Need To Fire For Johnson & Johnson's Oncology Business

(Forbes) Sept 24, 2015 - Johnson & Johnson‘s oncology business is not as strong as that of some of the other pharmaceutical companies, at least as far as future expected growth is concerned.
read article 

MedImmune and Tanabe Research Laboratories / Mitsubishi Tanabe Pharma Enter into Strategic Collaboration and Licensing Agreement for the Development of Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugates to Treat Cancer

(MedImmune) Sept 23, 2015 - MedImmune and Tanabe Research Laboratories U.S.A., Inc. today announced that they have entered into a strategic collaboration and licensing agreement under which TRL will use MedImmune’s pyrrolobenzodiazepine (PBD)-based warhead and linker technology to generate monospecific and bispecific antibody-drug conjugates (ADCs) for investigation in various cancers.
read corporate press release 

Syros Pharmaceuticals Licenses Clinical-Stage RARa Agonist to Develop and Commercialize for Genomically-Defined Cancer Populations Identified by Gene Control Platform

(MarketWatch) Sept 24, 2015 - Syros Pharmaceuticals, the industry pioneer in gene control, announced today that it entered into an exclusive license agreement with the Japanese oncology company TMRC Co. Ltd., to develop and commercialize tamibarotene in North America and Europe for cancer.
read article 

OncoRx Pharmaceuticals Inc. Announces Treatments for Therapy-resistant Tumors

(Yahoo! Finance) Sept 23, 2015 - OncoRx Pharmaceuticals, Inc. is announcing its launch as an early-stage pharmaceutical company focused on the development of drug therapies that control the progression of therapy-resistant malignant tumors.
read article 

BIND Therapeutics Announces Pfizer Inc. Exercises Option to Advance Nanoparticle-Based Kinase Inhibitor for Treatment of Solid Tumors

(BIND Therapeutics) Sept 24, 2015 - BIND Therapeutics, Inc., a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins, today announced that Pfizer Inc. exercised its option to obtain an exclusive license to develop and commercialize an Accurin drug candidate for the treatment of solid tumors under the companies' global collaboration agreement.
read corporate press release 

ASCO President Julie Vose, MD, to Give Keynote at AJMC’s Patient-Centered Oncology Care Meeting

(StreetInsider) Sept 24, 2015 - The fourth annual meeting of Patient-Centered Oncology Care, set for November 19-20, 2015, in Baltimore, Maryland, will feature a premiere multi-stakeholder lineup where leading payers, providers, and leaders from pharma will discuss how to deliver value-based care as cost of breakthrough therapies continues to climb.
read article 

Key Takeaways from NCCN Summit on Value, Access, & Cost of Cancer Care

(ACCCBuzz) Sept 23, 2015 - On September 11, 2015, the National Comprehensive Cancer Network (NCCN) convened healthcare experts for a policy summit on “Value, Access, and Cost of Cancer Care.”
read article 

Almost One Third of Families of Children with Cancer Have Unmet Basic Needs During Treatment

(Dana-Farber Cancer Institute) Sept 23, 2015 - Almost one-third of families whose children were being treated for cancer faced food, housing or energy insecurity and one-quarter lost more than 40 percent of household income, according to a new study from Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.
read press release 

AstraZeneca Presents Advances in Oncology Research at ECC 2015 with Data on AZD9291, durvalumab and LYNPARZA™ (Olaparib)

(AstraZeneca) Sept 24, 2015 - AstraZeneca, along with MedImmune, the company's global biologics research and development arm, will illustrate the strength and depth of research underpinning its scientific leadership in oncology, at the European Cancer Congress (ECC) 2015 in Vienna, Austria (25-29 September 2015).
read corporate press release 

MetaStat Announces Positive Topline Results of a MetaSite Breast(TM) Prognostic Study in Invasive Breast Cancer

(CNN Money) Sept 23, 2015 - MetaStat, Inc., a molecular diagnostic company, today announced positive preliminary results from a study of MetaSite Breast™ in patients with ER-positive, HER2-negative early stage invasive breast cancer.
read article  

New Cancer Genes Identified, Opening Door to Targeted Treatments

(UVA Health System) Sept 23, 2015 - In a discovery that could lead to more targeted and effective treatments for certain lung and prostate cancers, researchers at the School of Medicine have identified two new cancer-causing gene mutations – mutations that may be particularly susceptible to cancer-fighting drugs already approved by the federal Food and Drug Administration.
read press release 

Researchers Develop Strategy for Determining How Non-Coding Gene Sequences Contribute to Disease Risk

(Mass General) Sept 23, 2015 - A paper receiving advance online release in Nature Medicine describes a strategy for meeting one of today's most significant challenges in genomic medicine – determining whether a specific DNA variant in the non-protein-coding genome is the actual disease-causing variant of an associated disease risk.
read press release 

Arteries Better Than Veins for Liquid Biopsy

(Thomas Jefferson University) Sept 23, 2015 - Arteries contain higher numbers of circulating tumor cells than veins in uveal melanoma patients, raising a concern for standard technique for detection of tumor cells in the blood.
read press release 

One Size Doesn't Fit All: Patients with Metastatic Cancer May Need Stronger Anti-Coagulation Therapy Following Bone Lesion Surgery

(Thomas Jefferson University) Sept 21, 2015 - Jefferson researchers identified a high risk for venous thromboembolism (VTE), or blood clots, following surgery for long-bone reconstruction in patients with metastatic cancer.
read press release 

New Study Questions Clinical Trial Data for Kidney Cancer Drugs

(UNC Health Care) Sept 23, 2015 - Participants in stage III renal cell cancer drug trials are younger and healthier than many patients who don't qualify for research studies.
read press release 

Multiple Myeloma: Highly Active Combo Effective in Phase I Study

(MedPage Today) Sept 23, 2015 - The combination of carfilzomib, pomalidomide, and dexamethasone (CPD), a highly active combination for heavily-pretreated patients with relapsed or refractory multiple myeloma, was well tolerated in the first clinical trial to evaluate the combination in that population.
read article (free registration required)